Image via Endpoints News
Last updated
Bristol Myers Squibb: Partnership
Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.
Source: Endpoints News
The leadership read
Alliances like this can broaden biotech & pharma commercial leadership bench strength.
Market context: Against a Talent Market Index of 107.2 (Hot) (down 1.8 month-on-month), Americas is at rising (+10.6pts) on signal share.
Bristol Myers Squibb: 5 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.4% of MitchelLake's Asia signal flow; 5 tracked across 69 days.
MitchelLake in this thematic
Also at Bristol Myers Squibb →
More signals across Biotech & Pharma
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Partnership · Americas
BioDuro →BioDuro forms strategic partnership with CTI Biotechnology to create integrated platform from discovery to IND submission for preclinical drug development
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Intelligence powered by Autonodal ↗